Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.34 |
| ▸ | GSK3A | P49840 | 2/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2044013 | 0.79 | — | — | |
| SCHEMBL10527095 | 0.76 | ALDH1A1 (0.36) | ALOX15HSD17B10MEN1KMT2ATHRB | |
| SCHEMBL29550002 | 0.74 | AHR (0.48) | GSK3BPDE3BPDE3ACDK5CDK5R1 | |
| SCHEMBL659375 | 0.74 | AHR (0.48) | GSK3BPDE3BPDE3ACDK5CDK5R1 | |
| SCHEMBL4791581 | 0.72 | MKNK2 (0.30) | — | |
| SCHEMBL12210337 | 0.69 | TDP1 (0.45) | GSK3BCYP1A2SMN1; SMN2CDK5CDK5R1 | |
| SCHEMBL20206843 | 0.69 | CYP1A2 (0.52) | PDE3BPDE3ACYP1A2MEN1KMT2A | |
| SCHEMBL572199 | 0.69 | ALOX15 (0.63) | CYP1A2ALOX15HSD17B10BRPF1MEN1 | |
| SCHEMBL8805855 | 0.69 | BRPF1 (0.47) | CYP1A2ALOX15HSD17B10BRPF1MEN1 | |
| SCHEMBL673377 | 0.69 | CYP11B1 (0.42) | GSK3BPDE3BPDE3ACYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130371-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2004062666-A2 | USE OF RHO-KINASE INHIBITORRS FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | UNIVERSITY COLLEGE LONDON (GB) | 2004-07-29 | — | — | WO | disclosed |
| EP-0641781-B1 | 4-AMINO(ALKYL)CYCLOHEXANE-1-CARBOXAMIDE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5478838-A | Treating hypertension, angina pectoris, asthma, improving peripheral circulation | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0641781-A1 | 4-AMINO(ALKYL)CYCLOHEXANE-1-CARBOXAMIDE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130371-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | GSK3B 824/4885PDE3B 1389/4885PDE3A 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.